You can buy Lucigil at the lowest price at Nextgen.ooo online pharmacy. Gilteritinib is an AXL receptor tyrosine kinase inhibitor used to treat relapsed or refractory acute myeloid leukemia.
 
Gilteritinib, also known as ASP2215, is a small molecule FLT3 tyrosine kinase inhibitor that has greater selectivity and potency than other agents in this class. It is a pyrazine carboxamide derivative that has shown high selectivity for FLT3, preventing c-Kit-induced myelosuppression seen with other treatments. Gilteritinib was developed by Astellas Pharma and approved by the FDA on November 28, 2018. The drug was approved after being developed as an orphan drug with Fast Track and Priority Review status.
 
Acute myeloid leukemia is a cancer that affects the blood and bone marrow with rapid progression. This condition results in low normal blood cell counts and the need for ongoing blood transfusions.
Gilteritinib is a potent, selective inhibitor of both the internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations of the FLT3 receptor. In the same note, gilteritinib also inhibits the tyrosine kinases AXL and ALK. FLT3 and AXL are molecules involved in cancer cell growth. Gilteritinib's activity allows it to inhibit the phosphorylation of FLT3 and its downstream targets, such as STAT5, ERK, and AKT.
 
Interest in FLT3 transmembrane tyrosine kinases was heightened when studies reported that approximately 30% of patients with acute myeloid leukemia have a mutationally activated isoform. In addition, ITD mutation is associated with poor patient outcomes, while TKD mutation causes a mechanism of resistance to FLT3 tyrosine kinase inhibitors, and AXL tyrosine kinase tends to cause a mechanism of resistance to chemotherapy.